Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
- Overview
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2020
published in
- JAMA dermatology Journal
has subject area
- Administrative Claims, Healthcare
- Age Factors
- Aged
- Case-Control Studies
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Drug Prescriptions
- Female
- Humans
- Incidence
- Linagliptin
- Male
- Middle Aged
- Pemphigoid, Bullous
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Sulfonylurea Compounds
- United States